India Drug Delivery Devices Market Size, Share & Growth Forecast by 2033

MARKET OVERVIEW

The India drug delivery devices market was valued at USD 9.36 Billion in 2024 and is estimated to reach USD 15.31 Billion by 2033, growing at a CAGR of 5.62% during the forecast period 2025-2033. This growth is driven by government policies promoting domestic production, rising chronic disease prevalence, and advancements in drug delivery technologies. The report presents a thorough review featuring the India drug delivery devices market size, share, trends, and research of the industry.

STUDY ASSUMPTION YEARS

• Base Year: 2024
• Historical Year/Period: 2019-2024
• Forecast Year/Period: 2025-2033

INDIA DRUG DELIVERY DEVICES MARKET KEY TAKEAWAYS

• Current Market Size: USD 9.36 Billion in 2024
• CAGR: 5.62%
• Forecast Period: 2025-2033
• Increasing prevalence of chronic diseases like diabetes, cardiovascular, respiratory disorders, and cancer is fueling demand for advanced drug delivery systems.
• Technological innovations including smart drug delivery and needle-free technologies enhance patient compliance and treatment efficacy.
• Government policies and strategic foreign investments are encouraging domestic manufacturing expansion.
• Market segmentation covers route of administration, application, and end users.
• Regional breakdown includes North India, South India, East India, and West India.

Free Sample Download PDF

MARKET TRENDS

India is witnessing a significant rise in chronic diseases such as diabetes, cardiovascular conditions, respiratory diseases, and cancer, directly impacting demand for sophisticated drug delivery systems. The International Diabetes Federation projects India will have 92.97 million diabetic patients by 2030, boosting requirements for insulin pens, pumps, and transdermal patches. Pulmonary disorders such as asthma and COPD are increasing due to air pollution and lifestyle changes, with COPD being the second largest cause of death in India in 2019. This drives demand for inhalers, nebulizers, and nasal delivery devices targeting respiratory ailments.

Technological innovation is revolutionizing drug delivery in India. Smart drug delivery systems, connected devices, and automated injectors improve medication compliance and minimize errors. Wearable drug delivery systems and needle-free injectors reduce pain and discomfort, enhancing user adherence. Nanotechnology-driven delivery enables targeted therapies, notably in oncology and chronic disease management, promoting more personalized and effective treatments.

Growing adoption of self-administered devices like auto-injectors and pre-filled syringes supports convenience and reduces hospital visits. Digital healthcare integration further supports these technologies, enhancing treatment accessibility across urban and rural regions. These trends contribute significantly to the growth and transformation of the drug delivery devices market in India.

MARKET GROWTH FACTORS

Government initiatives encouraging local manufacturing and research boost the domestic drug delivery device market. Supportive policies promote investment and innovation in pharmaceutical device technology, facilitating production capacity expansion. Foreign medical device companies strategically investing in India enhance technology transfer and infrastructure growth, creating a competitive market environment conducive to long-term development.

Rising chronic disease incidence increases demand for novel drug delivery technologies. Chronic ailments like diabetes and respiratory diseases require reliable, patient-friendly devices that ensure targeted, efficient drug administration. The trend towards non-invasive drug delivery systems and home healthcare devices reflects patient preference for ease of use and minimizes healthcare facility dependency.

Expansion in healthcare infrastructure across India correlates with market growth. Improved medical facilities and rising health awareness widen the consumer base for drug delivery devices. Innovative products like inhaled insulin and pressurized metered-dose inhalers gaining regulatory approvals support market evolution, while increasing adoption of digital health technologies enhances delivery system efficiency and treatment outcomes.

Speak To an Analyst For a Customized Report

MARKET SEGMENTATION

Route of Administration:

• Injectable: Devices delivering drugs via injections, ensuring precise dosing for treatments requiring rapid absorption.
• Topical: Delivery devices for skin applications, facilitating localized therapy with minimal systemic absorption.
• Ocular: Devices designed for eye-related drug administration, enhancing targeted treatment efficacy.
• Others: Includes miscellaneous delivery routes not categorized above.

Application:

• Cancer: Devices specializing in targeted and controlled drug delivery for oncology therapies.
• Cardiovascular: Delivery systems designed for administering drugs treating heart and vascular conditions.
• Diabetes: Devices facilitating insulin and antidiabetic drug administration ensuring patient compliance.
• Infectious Diseases: Delivery tools for effective administration of antimicrobials and antivirals.
• Others: Encompasses applications beyond the major disease categories.

End User:

• Hospitals: Primary healthcare institutions using drug delivery devices for patient treatment.
• Ambulatory Surgical Centers: Facilities offering outpatient surgical care relying on advanced delivery devices.
• Others: Includes alternate healthcare providers and settings utilizing these devices.

REGIONAL INSIGHTS

The report segments the Indian market into North India, South India, East India, and West India. The document does not specify the dominant region or exact market shares among these. The overall growth trends and market segmentation suggest all regions partake in market expansion driven by chronic disease burden and healthcare infrastructure development.

RECENT DEVELOPMENTS & NEWS

• December 2024: Cipla received CDSCO approval to distribute and sell inhaled insulin in India, offering a needle-free diabetes treatment alternative, enhancing pulmonary drug delivery adoption.
• November 2024: AptarGroup inaugurated a new pharmaceutical plant in Taloja near Mumbai to locally manufacture components like pressurized metered dose inhaler valves, breath-actuated devices, and single-dose nasal sprays, bolstering local production capabilities and market growth.

KEY PLAYERS

• Cipla
• AptarGroup

CUSTOMIZATION NOTE:

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

ABOUT US

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

CONTACT US

IMARC Group,

134 N 4th St. Brooklyn, NY 11249, USA,

Email: sales@imarcgroup.com,

Tel No: (D) +91-120-433-0800,

United States: +1-201-971-6302